Scilex completes $27M repurchase of Penny Warrants from Oramed, eliminating dilution from 6.5M shares

Scilex Holding Co

Completed second tranche of warrant repurchase on Dec 30, 2025 for $14M, following $13M first tranche in Sep 2025.
Total repurchase price of $27M eliminated Penny Warrants exercisable at $0.01/share for 6.5M shares of common stock.
Oramed granted optionality in Jul 2025; Scilex paid $1.5M for the option to repurchase in two tranches.
All Penny Warrants originally issued Sep 21, 2023 have now been repurchased, removing a significant dilution overhang.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.